Clovis Oncology Inc. announced the first presentation of a comprehensive dataset from the company’s Phase 3 ARIEL3 study of rucaparib at the 2017 European Society for Medical Oncology (ESMO) Congress in Madrid.
Convert Prior Authorization Abandonments to Rx Fulfillments and Stop Leaving Money on the Table
Business, Electronic Health Records, Health Plans, Healthcare Communications Agencies, Healthcare Physicians, Manufacturers, NDA/MAA, Patients, Prescriptions, Prior Authorization (PA), Specialty Drugs, Specialty PharmacyA very high percentage of Prior Authorization (PA) requests are approved…but about 40% of these prescriptions are abandoned during the PA process, around 74.4 million prescriptions a year.